MedTrace Logo

Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT06444243 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-06-10

No results posted yet for this study

Summary

To explore the effectiveness of psilocybin-assisted therapy on reducing alcohol consumption in a double-blind, randomised, phase II clinical trial.

Conditions

Interventions

DRUG

Niacin

A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacin helps some enzymes work properly and helps skin, nerves, and the digestive tract stay healthy. Niacin is found in many plant and animal products. Niacin will be used at a concentration of 250mg as an active control.

DRUG

Psilocybin

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi.

Sponsors & Collaborators

  • Woke Pharmaceuticals

    collaborator UNKNOWN

  • University of Sydney

    lead OTHER

Principal Investigators

  • Paul Haber, PhD · University of Sydney

  • Kirsten C Morley, PhD · University of Sydney

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2025-07-31
Completion
2025-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06444243 on ClinicalTrials.gov